Does selection for short sleep duration explain human vulnerability to Alzheimer's disease?

Area of Science:

• Neuroscience
• Sleep Medicine
• Alzheimer's Disease Research

Background:

• Humans exhibit shorter sleep durations compared to other primates.
• There is a higher prevalence of Alzheimer's disease (AD) pathology in humans.
• Sleep plays a crucial role in brain maintenance and protection against neurodegenerative diseases.

Purpose of the Study:

• To review evidence supporting the hypothesis that reduced human sleep time impairs protective mechanisms against AD.
• To explore the link between sleep duration, the glymphatic system, melatonin, and AD pathology.
• To identify potential therapeutic targets for AD prevention and treatment based on sleep's role.

Main Methods:

• Review of existing scientific literature and evidence.
• Analysis of the glymphatic system's function during sleep.
• Examination of melatonin's antioxidant and anti-amyloidogenic properties.
• Investigation of the impact of sleep deprivation on amyloid-beta (eAβ) aggregation and AD.

Main Results:

• The glymphatic system clears brain interstitial fluid, including extracellular amyloid beta (eAβ), more efficiently during sleep.
• Melatonin, a sleep-associated hormone, acts as an antioxidant and inhibits eAβ polymerization into amyloid fibrils.
• Sleep deprivation is associated with increased plaque formation and AD, potentially creating a detrimental feedback loop.

Conclusions:

• Reduced sleep duration in humans may compromise essential physiological sleep-dependent mechanisms that protect against AD.
• This hypothesis suggests potential long-term side effects of sleep-reducing medications.
• Understanding sleep's role in AD pathogenesis may reveal novel strategies for AD prevention and treatment.